THROMBOCYTOPENIA DUE TO HEPARIN IN HAEMODIALYSIS PATIENTS
Main Article Content
Abstract
Objective: To study thrombocytopenia due to heparin in haemodialysis patients.
Material and Methods: This study was conducted in the Dialysis section of Nephrology Department Post Graduate Medical Institute, Lady Reading Hospital, Peshawar from January 2002 to December 2002. Patients with diagnosis of End Stage Renal Failure (ESRF), on maintenance haemodialysis for at least 3 months, were studied for thrombocytopenia due to heparin.
Inclusion criteria: Were All those patients were included in the study that were known case of End Stage Renal Failure (ESRF) and were on maintenance haemodialysis for at least three months or more. All age groups between 40 years and 60 years were included. Both male and female were included. Only Pakistani
Patients were included.
Exclusion criteria: Were Patients on dialysis in whom the cause of renal impairment is not yet found. Patients on haemodialysis maintenance for less than three months. Thrombocytopenia in ESRF patients due to some other cause. Age group below 40 years and above 60 years were excluded.
Results: Total number of haemodialysis performed in 276 ESRF patients were 3675 sessions. The mean age of the patients with thrombocytopenia due to heparin was 50 years (Range 40 – 60 years). The total number of patients sustained thrombocytopenia due to heparin were 15. Nine (60%) were female and six
(40%) were males. It was found that out of 276 ESRF patients who were on regular haemodialysis only nine (3.2%) patients had complications due to thrombocytopenia because of heparin.
Conclusion: Thrombocytopenia due to heparin was studied for the first time in NWFP and it was found that a minority of patients on maintenance haemodialysis develop thrombocytopenia due to heparin.
Material and Methods: This study was conducted in the Dialysis section of Nephrology Department Post Graduate Medical Institute, Lady Reading Hospital, Peshawar from January 2002 to December 2002. Patients with diagnosis of End Stage Renal Failure (ESRF), on maintenance haemodialysis for at least 3 months, were studied for thrombocytopenia due to heparin.
Inclusion criteria: Were All those patients were included in the study that were known case of End Stage Renal Failure (ESRF) and were on maintenance haemodialysis for at least three months or more. All age groups between 40 years and 60 years were included. Both male and female were included. Only Pakistani
Patients were included.
Exclusion criteria: Were Patients on dialysis in whom the cause of renal impairment is not yet found. Patients on haemodialysis maintenance for less than three months. Thrombocytopenia in ESRF patients due to some other cause. Age group below 40 years and above 60 years were excluded.
Results: Total number of haemodialysis performed in 276 ESRF patients were 3675 sessions. The mean age of the patients with thrombocytopenia due to heparin was 50 years (Range 40 – 60 years). The total number of patients sustained thrombocytopenia due to heparin were 15. Nine (60%) were female and six
(40%) were males. It was found that out of 276 ESRF patients who were on regular haemodialysis only nine (3.2%) patients had complications due to thrombocytopenia because of heparin.
Conclusion: Thrombocytopenia due to heparin was studied for the first time in NWFP and it was found that a minority of patients on maintenance haemodialysis develop thrombocytopenia due to heparin.
Article Details
How to Cite
1.
Akhtar SZ, Zahid S, Naeem M, Tahir M. THROMBOCYTOPENIA DUE TO HEPARIN IN HAEMODIALYSIS PATIENTS. J Postgrad Med Inst [Internet]. 2011 Jul. 28 [cited 2024 Nov. 25];23(2). Available from: https://jpmi.org.pk/index.php/jpmi/article/view/78
Issue
Section
Original Article
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.